文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

肝硬化危重患者接受连续性肾脏替代治疗的流行病学:HRS-HARMONY与CRRTnet登记库的同期平行分析

Epidemiology of Critically Ill Patients With Cirrhosis Undergoing Continuous Renal Replacement Therapy: A Contemporaneous Parallel Analysis of the HRS-HARMONY and CRRTnet Registries.
PubMed 文献 · Crit Care Med · 2026-09-17
一句话结论肝硬化/慢加急性肝衰竭危重患者启动CRRT后院内死亡率高,处方CRRT剂量>30 mL/kg/hr与更高院内死亡率独立相关。

本研究平行分析美国与加拿大三级学术医院HRS-HARMONY(n=245)与CRRTnet(n=206)两个登记库中ICU内接受CRRT的肝硬化/ACLF患者,描述CRRT剂量、模式及抗凝等过程因素,主要终点为院内死亡率。两队列出院存活率分别为34%和30%。HARMONY中AKI最常见病因为急性肾小管坏死(73%)和肝肾综合征-AKI(13%);CLIF-C ACLF评分较高与院内死亡率增加独立相关(HR 1.03,95%CI 1.01-1.05)。CRRTnet中最常用模式为连续性静脉-静脉血液透析滤过(83.8%),抗凝以局部枸橼酸抗凝(58.0%)或无抗凝(35.8%)为主;处方剂量>30 mL/kg/hr与更高院内死亡率独立相关(OR 2.69,95%CI 1.3-5.64)。存活者中64%出院前转为间歇性血液透析。

要点

  • 肝硬化/ACLF危重患者启动CRRT后出院存活率仅30%-34%,院内死亡率高。
  • HARMONY队列中CLIF-C ACLF评分每升高1分,院内死亡风险增加3%(HR 1.03,95%CI 1.01-1.05)。
  • CRRTnet中处方CRRT剂量>30 mL/kg/hr与院内死亡率升高独立相关(OR 2.69,95%CI 1.3-5.64)。
  • CRRTnet中最常用CRRT模式为CVVHDF(83.8%),抗凝以局部枸橼酸(58.0%)或无抗凝(35.8%)为主。
  • CRRTnet存活者中64%在出院前转为间歇性血液透析。

适用人群与场景

  • 美国与加拿大三级学术医院ICU内接受CRRT的肝硬化/慢加急性肝衰竭(ACLF)危重患者。
  • HARMONY队列n=245(中位年龄57岁,女性41%),CRRTnet队列n=206(年龄58岁,女性39%)。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体的CRRT处方剂量调整方案或药物剂量。
  • CRRTnet中最常用CRRT模式为连续性静脉-静脉血液透析滤过(83.8%)。
  • CRRTnet中最常用抗凝策略为局部枸橼酸抗凝(58.0%)或无抗凝(35.8%)。
  • CRRTnet存活者中64%在出院前转为间歇性血液透析(IHD)。

红旗征与不能漏的情况

  • 原文未提及具体的红旗征或需立刻处理的情况。

研究设计与关键结果

  • 研究类型:基于HRS-HARMONY与CRRTnet两个登记库的同期平行分析(观察性研究),非干预性。
  • 样本量与中心数:HARMONY队列n=245,CRRTnet队列n=206;来自美国与加拿大三级学术医院。
  • 人群:ICU内接受CRRT的肝硬化/ACLF危重患者。
  • 主要终点:院内死亡率。HARMONY出院存活率34%,CRRTnet出院存活率30%。
  • HARMONY:AKI最常见病因为急性肾小管坏死(73%)和肝肾综合征-AKI(13%),存活者与非存活者间无显著差异(p=0.24)。
  • HARMONY:较高的CLIF-C ACLF评分与院内死亡率增加独立相关(HR 1.03,95%CI 1.01-1.05;p<0.001)。
  • CRRTnet:处方CRRT剂量>30 mL/kg/hr与更高院内死亡率独立相关(多变量回归OR 2.69,95%CI 1.3-5.64;p=0.01);存活者中64%出院前转为IHD。

证据类型、等级与局限

  • 证据类型:基于两个登记库的观察性平行分析(非RCT)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:观察性设计,无法排除混杂;原文未提及单中心、回顾性等具体局限。

对床旁实践的改变

  • 对肝硬化/ACLF危重患者启动CRRT时,应知晓其院内死亡率高(出院存活率30%-34%)。
  • 处方CRRT剂量>30 mL/kg/hr与更高院内死亡率独立相关,提示避免常规处方高剂量CRRT,但因果关系需前瞻性验证。
  • 局部枸橼酸抗凝在该人群中常用(58.0%),尽管存在枸橼酸毒性担忧。
  • 存活者中多数(64%)出院前可转为间歇性血液透析。

指南或共识出处

  • HRS-HARMONY登记库与CRRTnet登记库(原文未提供具体指南或共识名称)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: Describe the epidemiology of patients with cirrhosis/acute-on-chronic liver failure (ACLF) receiving continuous renal replacement therapy (CRRT) pertaining to process factors including renal replacement dose, modality, and circuit anticoagulation.

SETTING: Academic tertiary care hospitals in the United States and Canada.

DESIGN AND PATIENTS: We performed a parallel study of contemporaneous data from the HARMONY and CRRT network (CRRTnet) databases to describe the epidemiology and process of CRRT care of cirrhosis/ACLF patients receiving CRRT in the ICU. We evaluated clinical and CRRT process factors (dialysis dose, anticoagulation) with the primary outcome of in-hospital mortality.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: The HARMONY cohort (n = 245; median age, 57 yr; 41% female) and CRRTnet cohort (n = 206; 58 yr; 39% female) demonstrated similar overall survival to hospital discharge (HARMONY, 34%; CRRTnet, 30%). In HARMONY, the two most common causes of acute kidney injury (AKI) requiring CRRT were acute tubular necrosis (73%) and hepatorenal syndrome-AKI (13%), with no significant difference between survivors and nonsurvivors (p = 0.24). In HARMONY, higher chronic liver failure-C ACLF scores (hazard ratio, 1.03 [95% CI, 1.01-1.05]; p < 0.001) were independently associated with increased in-hospital mortality. In CRRTnet, the most common CRRT modality was continuous venovenous hemodiafiltration (83.8%), and the most common anticoagulation strategy was regional citrate anticoagulation (58.0%) or no anticoagulation (35.8%). CRRT prescribed dose greater than 30 mL/kg/hr was independently associated with higher in-hospital mortality (multivariable regression; odds ratio, 2.69; 95% CI, 1.3-5.64; p = 0.01). Of survivors in CRRTnet, 64% were transitioned to intermittent hemodialysis (IHD) before hospital discharge.

CONCLUSIONS: Critically ill cirrhosis/ACLF patients initiated on CRRT in the absence of liver transplantation had high in-hospital mortality. These patients were prescribed higher initial CRRT doses (median total effluent > 30 mL/kg/hr), with higher CRRT dose independently associated with increased in-hospital mortality. Of ICU survivors, 64% were transitioned to IHD at ICU discharge. Despite concerns for citrate toxicity, citrate regional anticoagulation was commonly employed in these patients.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Karvellas CJ, Lambert J, Ouyang T, et al. Epidemiology of Critically Ill Patients With Cirrhosis Undergoing Continuous Renal Replacement Therapy: A Contemporaneous Parallel Analysis of the HRS-HARMONY and CRRTnet Registries. Crit Care Med. 2026. PMID: 42752385. doi:10.1097/CCM.0000000000007363

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。